Oncología clínica

(JIF 2023)

-Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan O, Handzhiev S, Izumi H, Lee JS, Dziadziuszko R, Wolf J, Blackhall F, Reck M, Alvarez JB, Hummel HD, Dingemans A, Sands J, Akamatsu H, Owonikoko TK, Ramalingam SS, Borghaei H, Johnson ML, Huang S, Mukherjee S, Minocha M, Jiang TY, Martinez P, Anderson ES, Paz L, DeLLphi I. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. NEW ENGLAND JOURNAL OF MEDICINE. 2023; DOI:10.1056/NEJMoa2307980. PMID:37861218. IF:96,200 (Q1/1D). Document type: Article.

-Annesi I, Cecchi L, Biagioni B, Chung KF, Clot B, Coen MC, Amato GD, Damialis A, Dominguez J, Galan C, Gilles S, Holgate S, Jeebhay M, Kazadzis S, Papadopoulos NG, Quirce S, Sastre J, Tummon F, Traidl C, Walusiak J, Alonso P, Canelo C, Cantero Y, Rigau D, Salazar J, Verdugo F, Jutel M, Akdis CA, Agache I. Is exposure to pollen a risk factor for moderate and severe asthma exacerbations?. ALLERGY. 2023; 78(8). DOI:10.1111/all.15724. PMID:36961370. IF:12,600 (Q1/1D). Document type: Review.

-Arqueros C, Salazar J, Gallardo A, Andrés M, Tibau A, Bell OL, Artigas A, Lasa A, Cajal T, Lerma E, Barnadas A. Secreted Protein Acidic and Rich in Cysteine (SPARC) Polymorphisms in Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer Patients. Biomedicines. 2023; 11(12):3231. DOI:10.3390/biomedicines11123231. PMID:38137452. IF:3,900 (Q1/3D). Document type: Article.

-Bertran J, Giménez A, Román R, Talbot S, Whiteley R, Floc’h N, Martínez E, Martin MJ, Smith PD, Sullivan I, Terp MG, Saeh J, Marino C, Fabbri G, Guo G, Xu M, Tornador C, Aguilar A, Reguart N, Ditzel HJ, Martínez A, Nabau N, Gascó A, Rosell R, Pease JE, Polanska UM, Travers J, Urosevic J, Molina MA. BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors. Molecular Cancer. 2023; 22(1):110. DOI:10.1186/s12943-023-01815-w. PMID:37443114. IF:27,700 (Q1/1D). Document type: Article.

-Blakely CM, Weder W, Bubendorf L, He J, Majem M, Shyr Y, Chaft JE. Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: A review. LUNG CANCER. 2023; 177. DOI:10.1016/j.lungcan.2023.01.002. PMID:36736076. IF:4,500 (Q1/2D). Document type: Review.

-Blanco R, Dómine M, González JL, Loutfi S, Alfaro J, Saldaña J, Rubio J, Campos B, Hidalgo J, Barba A, Márquez D, Martin M, Olaverri A, Nadal E. Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes. LUNG CANCER. 2023; 183:107318. DOI:10.1016/j.lungcan.2023.107318. PMID:37557022. IF:4,500 (Q1/2D). Document type: Article.

-Bracchiglione J, Rodríguez G, Requeijo C, Santero M, Salazar J, Salas K, Meade A-G, Antequera A, Auladell A, Quintana MJ, Solà I, Urrútia G, Acosta R, Bonfill X. Systemic Oncological Treatments versus Supportive Care for Patients with Advanced Hepatobiliary Cancers: An Overview of Systematic Reviews. Cancers. 2023; 15(3):766. DOI:10.3390/cancers15030766. PMID:36765723. IF:4,500 (Q1/3D). Document type: Review.

-Campos F, Téres R, Sebio A, Bettim BB, Martinez J. Survival Differences of Patients with Resected Extraskeletal Osteosarcoma  Receiving Two Different (Neo)Adjuvant Chemotherapy Regimens: A Systematic Review  and Meta-analysis. CLINICAL ONCOLOGY. 2023; 35(12). DOI:10.1016/j.clon.2023.09.009. PMID:37777356. IF:3,200 (Q2/5D). Document type: Article.

-Canto E, Anguera G, Jimenez N, Mellado B, Ramirez O, Mariscal A, Maroto P, Vidal S. Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment. Diagnostics. 2023; 13(13):2222. DOI:10.3390/diagnostics13132222. PMID:37443615. IF:3,000 (Q1/2D). Document type: Article.

-Carmona E, Aguado M, Tubau C, Sánchez S, Mozos A, Sullivan I, Spertino J. Epidermolysis bullosa acquisita induced by atezolizumab. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. 2023; DOI:10.1111/ddg.15203. PMID:37658659. IF:5,500 (Q1/1D). Document type: Letter.

-Casanovas A, Sebio R, Ciendones M, Cuartero J, Estanyol B, Padrós J, García B, Barnadas A, Masia J. Prehabilitation in Patients With Breast Cancer Receiving Neoadjuvant Therapy to  Minimize Musculoskeletal Postoperative Complications and Enhance Recovery  (PREOPtimize): A Protocol for a Randomized Controlled Trial. PHYSICAL THERAPY. 2023; 103(9):pzad062. DOI:10.1093/ptj/pzad062. PMID:37318267. IF:3,500 (Q1/1D). Document type: Article.

-Chmielecki J, Gray JE, Cheng Y, Ohe Y, Imamura F, Cho BC, Lin MC, Majem M, Shah R, Rukazenkov Y, Todd A, Markovets A, Barrett JC, Hartmaier RJ, Ramalingam SS. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature Communications. 2023; 14(1):1070. DOI:10.1038/s41467-023-35961-y. PMID:36849494. IF:14,700 (Q1/1D). Document type: Article.

-De Castro J, Insa A, Collado R, Escudero V, Martínez A, Fernandez E, Sullivan I, Arrabal N, Carcedo D, Manzaneque A. Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain. BMC Pulmonary Medicine. 2023; 23(1):69. DOI:10.1186/s12890-023-02356-0. PMID:36809990. IF:2,600 (Q2/5D). Document type: Article.

-de Velasco G, Alonso T, Rodríguez A, Anguera G, Campayo M, Pinto Á, Ortega EM, Gallardo E, Núñez NF, García I, Reig O, Méndez MJ, Fernández O, Cassinello NV, Torregrosa D, López A, Rosero A, Valiente PG, de España CG, Climent MA, Santasusana MD, Sánchez ÁR, González IC, Afonso R, García del Muro X, Casinello J, Fernández EM, García L, Afonso J, Polo SH, Asensio Ú. Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib. Clinical Genitourinary Cancer. 2023; 21(3):e166-e174. DOI:10.1016/j.clgc.2022.11.021. PMID:36610891. IF:2,300 (Q2/5D). Document type: Article.

-Escuin D, López L, Bell O, Mora J, García B, Moral A, Clos M, Boronat L, Arqueros C, Barnadas A. Circulating miRNA Expression Is Inversely Correlated with Tumor Tissue or  Sentinel Lymph Nodes in Estrogen Receptor-Positive Early Breast Cancer Patients. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023; 24(17):13293. DOI:10.3390/ijms241713293. PMID:37686099. IF:4,900 (Q1/3D). Document type: Article.

-Fiala O, Buti S, Takeshita H, Okada Y, Massari F, Palacios GA, Dionese M, Scagliarini S, Büttner T, Fornarini G, Myint ZW, Galli L, Souza VC, Pichler R, De Giorgi U, Quiroga MNG, Gilbert D, Popovic L, Grande E, Mammone G, Berardi R, Crabb SJ, Molina J, Freitas M, Luz M, Iacovelli R, Calabrò F, Tural D, Atzori F, Küronya Z, Chiari R, Campos S, Caffo O, Fay AP, Kucharz J, Zucali PA, Rinck JA, Zeppellini A, Bastos DA, Aurilio G, Mota A, Trindade K, Ortega C, Sade JP, Rizzo M, Vau N, Giannatempo P, Barillas A, Monteiro FSM, Dauster B, Cattrini C, Nogueira L, de Carvalho R, Seront E, Aceituno LG, Grillone F, Cutuli HJ, Fernandez M, Bassanelli M, Roviello G, Abahssain H, Procopio G, Milella M, Kopecky J, Martignetti A, Messina C, Caitano M, Inman E, Kanesvaran R, Herchenhorn D, Santini D, Manneh R, Bisonni R, Zakopoulou R, Mosca A, Morelli F, Maluf F, Soares A, Nunes F, Pinto A, Zgura A, Incorvaia L, Ansari J, Zabalza IO, Landmesser J, Rizzo A, Mollica V, Sorgentoni G, Battelli N, Porta C, Bellmunt J, Santoni M. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study. CANCER IMMUNOLOGY IMMUNOTHERAPY. 2023; 72(11). DOI:10.1007/s00262-023-03518-z. PMID:37676282. IF:4,600 (Q1/3D). Document type: Article.

-Frezza AM, Stacchiotti S, Chibon F, Coindre JM, Italiano A, Romagnosa C, Bagué S, Dei AP, Braglia L, Palmerini E, Quagliuolo V, Broto JM, Pousa AL, Grignani G, Brunello A, Blay JY, Beveridge RD, Lugowska I, Lesluyes T, Maestro R, Merlo FD, Casali PG, Gronchi A. CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study. Cancer Medicine. 2023; 12(2). DOI:10.1002/cam4.5015. PMID:35848358. IF:2,900 (Q2/5D). Document type: Article.

-Fumagalli C, Orellana R, Ferre M, Gonzalez A, Catasus L, Vazquez T, Sebio A, Lopez A, Llauger J, Peiro A, Antonescu CR. Expanding the molecular landscape of undifferentiated sarcomas of bone with a novel EWSR1-SSX3 gene fusion. GENES CHROMOSOMES & CANCER. 2023; 63(1). DOI:10.1002/gcc.23215. PMID:38050902. IF:3,100 (Q2/4D). Document type: Article.

-Garcia JA, Blancas I, Echavarria I, Hinojo C, Margeli M, Moreno F, Pernas S, Cajal TRY, Ribelles N, Bellet M. SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022). Clinical & Translational Oncology. 2023; 25(9). DOI:10.1007/s12094-023-03203-8. PMID:37148499. IF:2,800 (Q2/5D). Document type: Article.

-Garcia R, González B, Vidal R, Contreras D, Pericay C, Fernández A, Falcó E, González M, Reina JJ, Alonso V, Rodríguez N, Gil M, Santos C, Páez D, Anton B, Aguilar F, Morales P. Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain. Clinical & Translational Oncology. 2023; DOI:10.1007/s12094-023-03309-z. PMID:37651021. IF:2,800 (Q2/5D). Document type: Article.

-Garcia R, Sullivan I, Arriola E, Insa A, Vidal O, Cruz P, Moran T, Reguart N, Zugazagoitia J, Domine M. SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022). Clinical & Translational Oncology. 2023; 25(9). DOI:10.1007/s12094-023-03216-3. PMID:37418123. IF:2,800 (Q2/5D). Document type: Article.

-Giménez A, Sánchez E, de Lope LR, Aguilar A, Sullivan I, Calvo V, Moya I, Viteri S, Cabrera C, Aguado C, Armiger N, Valarezo J, Mayo C, Reguart N, Rosell R, Provencio M, Romero A, Molina MA. Detecting ALK, ROS1, and RET fusions and the MET?ex14 splicing variant in liquid biopsies of non-small-cell lung cancer patients using RNA-based techniques. Molecular Oncology. 2023; 17(9). DOI:10.1002/1878-0261.13468. PMID:37243883. IF:5,000 (Q1/3D). Document type: Article.

-González S, Molina V, Homs R, Martín B, Rodríguez M, González JA, López A, Moral A, Sánchez S. Surgical and oncological results after surgical treatment of patients diagnosed with sarcoma liver metastases. CIRUGIA ESPANOLA. 2023; 101(2). DOI:10.1016/j.ciresp.2021.11.005. PMID:35901963. IF:1,300 (Q3/7D). Document type: Article.

-Gray JE, Ahn MJ, Oxnard GR, Shepherd FA, Imamura F, Cheng Y, Okamoto I, Cho BC, Lin MC, Wu YL, Majem M, Gautschi O, Boyer M, Bulusu KC, Markovets A, Barrett JC, Hodge R, McKeown A, Hartmaier RJ, Chmielecki J, Papadimitrakopoulou VA, Ramalingam SS. Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a  Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer;  Exploratory Analysis from AURA3 and FLAURA. CLINICAL CANCER RESEARCH. 2023; 29(17). DOI:10.1158/1078-0432.CCR-22-3146. PMID:37379430. IF:10,400 (Q1/1D). Document type: Article.

-Grünwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C, Motzer R, Hutson TE, Méndez MJ, Hong S-H, Winquist E, Goh JC, Maroto P, Buchler T, Takagi T, Burgents JE, Perini R, He C, Okpara CE, McKenzie J, Choueiri TK. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Frontiers in Oncology. 2023; 13:1223282. DOI:10.3389/fonc.2023.1223282. PMID:37664025. IF:3,500 (Q2/4D). Document type: Article.

-Grunwald V, Powles T, Kopyltsov E, Kozlov V, Alonso T, Eto M, Hutson T, Motzer R, Winquist E, Maroto P, Keam B, Procopio G, Wong SR, Melichar B, Rolland F, Oya M, Rodriguez K, Saito K, McKenzie J, Porta C. Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study. European Urology Oncology. 2023; 6(4). DOI:10.1016/j.euo.2023.01.010. PMID:36720658. IF:8,300 (Q1/1D). Document type: Article.

-Herbst RS, Wu Y-L, John T, Grohe C, Majem M, Wang J, Kato T, Goldman JW, Laktionov K, Kim S-W, Yu C-J, Vu HV, Lu S, Lee KY, Mukhametshina G, Akewanlop C, De Marinis F, Bonanno L, Domine M, Shepherd FA, Urban D, Huang X, Bolanos A, Stachowiak M, Tsuboi M. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(10). DOI:10.1200/JCO.22.02186. PMID:36720083. IF:42,100 (Q1/1D). Document type: Article.

-Isla D, Felip E, Garrido P, Insa A, Majem M, Remon J, Trigo JM, de Castro J. A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study. Clinical & Translational Oncology. 2023; 25(1). DOI:10.1007/s12094-022-02941-5. PMID:36168085. IF:2,800 (Q2/5D). Document type: Article.

-Isla D, Sanchez A, Casal J, Cobo M, Majem M, Reguart N, Zugazagoitia J, Bernabe R. PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement. Journal of Clinical Medicine. 2023; 12(15):5063. DOI:10.3390/jcm12155063. PMID:37568465. IF:3,000 (Q1/2D). Document type: Article.

-Jimenez P, Foy V, Raby S, Carmona A, Macía L, Arrazubi V, Cacho D, Hernandez San Gil R, Custodio A, Cano JM, Fernández A, Mirallas O, Macias I, Vidal R, Visa L, Limón ML, Pimentel P, Martínez N, Sauri T, Martín M, Mangas M, Gil M, Calvo A, Reguera P, Granja M, Martín A, Hernández C, Cerdá P, Gomez L, Garcia F, Pacheco V, Gutierrez D, Ruiz M, Weaver J, Mansoor W, Gallego J. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy. Therapeutic Advances in Medical Oncology. 2023; 15:17588359231157641. DOI:10.1177/17588359231157641. PMID:36895850. IF:4,300 (Q2/3D). Document type: Article.

-John T, Grohé C, Goldman JW, Shepherd FA, de Marinis F, Kato T, Wang Q, Su W-C, Choi JH, Sriuranpong V, Melotti B, Fidler MJ, Chen J, Albayaty M, Stachowiak M, Taggart S, Wu Y-L, Tsuboi M, Herbst RS, Majem M. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial. Journal of Thoracic Oncology. 2023; 18(9). DOI:10.1016/j.jtho.2023.05.015. PMID:37236398. IF:21,000 (Q1/1D). Document type: Article.

-John T, Majem M, Legg D, Goldman J. Current and Future Perspectives of Health-Related Quality of Life in Resectable EGFR-Mutated Non-Small Cell Lung Cancer: A Podcast. Targeted Oncology. 2023; 18(1). DOI:10.1007/s11523-022-00927-5. PMID:36534268. IF:4,400 (Q2/3D). Document type: Editorial Material.

-Kobel M, Kang EY, Weir A, Rambau PF, Lee CH, Nelson GS, Ghatage P, Meagher NS, Riggan MJ, Alsop J, Anglesio MS, Beckmann MW, Bisinotto C, Boisen M, Boros J, Brand AH, Brooks A, Carney ME, Coulson P, Courtney M, Cushing KL, Cybulski C, Deen S, El MA, Elishaev E, Erber R, Fereday S, Fischer A, Gayther SA, Barquin A, Gentry A, Gilks CB, Gronwald H, Grube M, Harnett PR, Harris HR, Hartkopf AD, Hartmann A, Hein A, Hendley J, Hernandez BY, Huang YJ, Jakubowska A, Jimenez M, Jones ME, Kennedy CJ, Kluz T, Koziak JM, Lesnock J, Lester J, Lubinski J, Longacre TA, Lycke M, Mateoiu C, McCauley BM, McGuire V, Ney B, Olawaiye A, Orsulic S, Osorio A, Paz L, Cajal TRY, Rothstein JH, Ruebner M, Schoemaker MJ, Shah MT, Sharma R, Sherman ME, Shvetsov YB, Singh N, Steed H, Storr SJ, Talhouk A, Traficante N, Wang C, Whittemore AS, Widschwendter M, -Wilkens LR, Winham SJ, Benitez J, Berchuck A, Bowtell DD, dos FJC, Campbell I, Cook LS, DeFazio A, Doherty JA, Fasching PA, Fortner RT, Garcia MJ, Goodman MT, Goode EL, Gronwald J, Huntsman DG, Karlan BY, Kelemen LE, Kommoss S, Le ND, Martin SG, Menon U, Modugno F, Pharoah PDP, Schildkraut JM, Sieh W, Staebler A, Sundfeldt K, Swerdlow AJ, Ramus SJ, Brenton JD, AOCS GRP. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study. Journal of Pathology Clinical Research. 2023; 9(3). DOI:10.1002/cjp2.311. PMID:36948887. IF:3,400 (Q1/3D). Document type: Article.

-López A, González P, Sanz J, Prieto JD, Trias I, Luque RJ, Semidey ME, Maroto P, Algaba F. Practical aspects of PD-L1 assessment in the treatment of urothelial carcinoma: Consensus of the uropathology group of the SEAP. Revista Espanola De Patologia. 2023; 56(4). DOI:10.1016/j.patol.2023.05.001. PMID:37879823. Document type: Review.

-Lozano R, Castro E, FL, Thorne H, Ramirez M, Aragon IM, Cendon Y, Gutierrez A, Salles DC, Romero N, Lorente D, Gonzalez P, Calatrava A, Alonso C, Anido U, Arevalo S, Balmana J, Chirivella I, Juan MJ, Llort G, Cajal TRY, Almagro E, Alameda D, Lopez PP, Herrera B, Mateo J, Pritchard CC, Antonarakis ES, Lotan TL, Rubio J, Sandhu S, Olmos D. Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers. EUROPEAN JOURNAL OF CANCER. 2023; 185. DOI:10.1016/j.ejca.2023.02.022. PMID:36972661. IF:7,600 (Q1/2D). Document type: Article.

-Macaulay VM, Lord S, Hussain S, Maroto JP, Jones RH, Climent MÁ, Cook N, Lin CC, Wang SS, Bianchini D, Bailey M, Schlieker L, Bogenrieder T, de Bono J. A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer. BRITISH JOURNAL OF CANCER. 2023; 129(6). DOI:10.1038/s41416-023-02380-1. PMID:37537253. IF:6,400 (Q1/2D). Document type: Article.

-Manzano JL, Martin J, Fernández LA, Benítez G, Medina J, Quindós M, García A, Fernández O, Simo RV, Majem M, Bellido L, Ayala de Miguel P, Campos B, Espinosa E, Macías JA, Gil I, Lorente D, Rodriguez A, Perez VN, López R, Gramaje MG, Puértolas T, Rodriguez JF, Espasa L, Belaustegui G, Cerezuela P. Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma: DESCRIBE-AD real-world retrospective observational study. MELANOMA RESEARCH. 2023; 33(5). DOI:10.1097/CMR.0000000000000888. PMID:36988401. IF:1,500 (Q3/7D). Document type: Article.

-Martin J, Martinez J, Moura DS, Redondo A, Gutierrez A, Lopez A, Martinez J, Sevilla I, Diaz R, Solis MP, Carnero A, Perez M, Marcilla D, Garcia J, Romero P, Fernandez J, Lopez D, Arribas I, Hindi N. Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A. Signal Transduction and Targeted Therapy. 2023; 8(1):405. DOI:10.1038/s41392-023-01661-8. IF:40,800 (Q1/1D). Document type: Article.

-Martinez DAS, Quilez A, Jimenez P, Sesma A, Tarazona N, Pacheco V, Obispo B, Paez D, Quintanar T, Sanchez M, Montes AF, Felip E, Rodriguez A, Elez E. Current professional standing of young medical oncologists in Spain: a nationwide survey by the Spanish Society of Medical Oncology + MIR section. Clinical & Translational Oncology. 2023; 25(3). DOI:10.1007/s12094-022-02989-3. PMID:36418642. IF:2,800 (Q2/5D). Document type: Article.

-Martinez N, Vilarino N, Alameda F, Mojal S, Arumi M, Carrato C, Aldecoa I, Ribalta T, Vidal N, Bellosillo B, Menendez S, Del Barco S, Gallego O, Pineda E, Lopez R, Hernandez A, Mesia C, Esteve A, de la Iglesia N, Balana C, Martinez M, Navarro P. Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker. Cells. 2023; 12(6):843. DOI:10.3390/cells12060843. PMID:36980184. IF:5,100 (Q2/4D). Document type: Article.

-Mayayo C, de Heredia ML, Prat E, Gonzalez L, Guarch ME, Vilches C, Munoz L, Asensi MA, Serra C, Llebaria A, Casado M, Artuch R, Garrabou G, Garcia PM, Pallardo FV, Nunes V. The antioxidant L-Ergothioneine prevents cystine lithiasis in the Slc7a9-/- mouse model of cystinuria. Redox Biology. 2023; 64:102801. DOI:10.1016/j.redox.2023.102801. PMID:37418888. IF:10,700 (Q1/1D). Document type: Article.

-Nadal E, Oré M, Remon J, Bernabé R, Covela M, de Castro J, Massutí B, Guillot M, Majem M, Maestu I, Morilla I, Gironés R. Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer. Clinical & Translational Oncology. 2023; 25(11). DOI:10.1007/s12094-023-03286-3. PMID:37566345. IF:2,800 (Q2/5D). Document type: Article.

-Nadal E, Rodríguez D, Simó M, Massutí B, Juan O, Huidobro G, López R, De Castro J, Estival A, Mosquera J, Sullivan I, Felip E, Blasco A, Guirado M, Pereira E, Vilariño N, Navarro V, Bruna J. Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for  Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated  Brain Metastases (Atezo-Brain, GECP17/05). JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(28). DOI:10.1200/JCO.22.02561. PMID:37603816. IF:42,100 (Q1/1D). Document type: Article.

-O’Donnell PH, Milowsky MI, Petrylak DP, Hoimes CJ, Flaig TW, Mar N, Moon HH, Friedlander TW, McKay RR, Bilen MA, Srinivas S, Burgess EF, Ramamurthy C, George S, Geynisman DM, Bracarda S, Borchiellini D, Geoffrois L, Maroto JP, Ferrario C, Carret A-S, Yu Y, Guseva M, Homet B, Rosenberg JE. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(25). DOI:10.1200/JCO.22.02887. PMID:37369081. IF:42,100 (Q1/1D). Document type: Article.

-Peters S, Letovanec I, Mauer M, Dafni U, Ejedepang D, Biernat W, Bubendorf L, Warth A, Pokharel S, Reinmuth N, Tarruella MM, Casas J, Tsourti Z, Marti N, Kammler R, Danson S, O’Brien M, Stahel RA. Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial. LUNG CANCER. 2023; 175. DOI:10.1016/j.lungcan.2022.12.004. PMID:36535121. IF:4,500 (Q1/2D). Document type: Article.

-Pilcher L, Pahlke S, Urquhart O, O’Brien KK, Dhar V, Fontana M, Gonzalez C, Keels MA, Mascarenhas AK, Nascimento MM, Platt JA, Sabino GJ, Slayton RL, Tinanoff N, Young DA, Zero DT, Tampi MP, Purnell D, Salazar J, Megremis S, Bienek D, Carrasco A. Direct materials for restoring caries lesions Systematic review and meta-analysis-a report of the American Dental Association Council on Scientific Affairs. JOURNAL OF THE AMERICAN DENTAL ASSOCIATION. 2023; 154(2). DOI:10.1016/j.adaj.2022.09.012. PMID:36610925. IF:3,100 (Q1/2D). Document type: Article.

-Provencio M, Estival A, Franco F, López G, Saigí M, Arasanz H, Diz P, Carcereny E, García J, Aguado C, Mosquera J, Iruarrizaga E, Majem M, Bosch J, Mielgo X, Guirado M, Juan Ó, Blasco A, Lucía C, Del Barrio A, De Portugal T, López A, Serrano G, Campos B, Rubio J, Catot S, Esteban B, Martí JL, del Barco E, Calvo V. Immunogenicity of COVID-19 vaccines in lung cancer patients. LUNG CANCER. 2023; 184:107323. DOI:10.1016/j.lungcan.2023.107323. PMID:37639820. IF:4,500 (Q1/2D). Document type: Article.

-Provencio M, Ortega AL, Coves J, Calvo V, Marsé R, Dómine M, Guirado M, Carcereny E, Fernández N, Álvarez R, Blanco R, León L, Sánchez JM, Sullivan IG, Cobo M, Sánchez A, Massuti B, Sierra B, Mártinez C, Serna R, Romero A, Cruz A. Atezolizumab Plus Bevacizumab as First-line Treatment for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer with High Tumor Mutation Burden: A Nonrandomized Controlled Trial. JAMA Oncology. 2023; 9(3). DOI:10.1001/jamaoncol.2022.5959. PMID:36520426. IF:22,500 (Q1/1D). Document type: Article.

-Remon J, Besse B, Aix SP, Callejo A, Al K, Bernabe R, Greillier L, Majem M, Reguart N, Monnet I, Cousin S, Garrido P, Robinet G, Campelo RG, Madroszyk A, Mazieres J, Curcio H, Wasag B, Pretzenbacher Y, Fournier B, Dingemans A, Dziadziuszko R. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial. ANNALS OF ONCOLOGY. 2023; 34(5). DOI:10.1016/j.annonc.2023.02.012. PMID:36863484. IF:56,700 (Q1/1D). Document type: Article.

-Rodriguez A, Maroto P, Font A, Martin C, Mellado B, Corbera A, Orrillo M, Reig O, Querol R, Rios A, Cano L, Alonso J, Martinez G, Galtes S, Taus A, Martinez M, Juanpere N, Juan O, Bellmunt J. Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study. BRITISH JOURNAL OF CANCER. 2023; 128(1). DOI:10.1038/s41416-022-01991-4. PMID:36289372. IF:6,400 (Q1/2D). Document type: Article.

-Roldan JM, Valdivia C, Santos M, Lanillos J, Maroto P, Anguera G, Calsina B, Martinez A, Monteagudo M, Mellid S, Leandro LJ, Montero C, Cascon A, Roncador G, Coloma J, Robledo M, Rodriguez C. Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition. INTERNATIONAL JOURNAL OF CANCER. 2023; 153(6). DOI:10.1002/ijc.34575. PMID:37260183. IF:5,700 (Q1/2D). Document type: Article.

-Rueda A, Mendoza JI, Alba L, Parladé E, Voltà E, Paez D, Aviño A, Eritja R, Vázquez E, Villaverde A, Mangues R, Unzueta U. Site-directed cysteine coupling of disulfide-containing non-antibody carrier proteins (THIOCAPs). Science China-Materials. 2023; 66(10). DOI:10.1007/s40843-023-2571-6. IF:6,800 (Q1/3D). Document type: Article.

-Salazar J, Bracchiglione J, Savall O, Antequera A, Bottaro D, Gutierrez M, Martinez S, Pericay C, Tibau A, Bonfill X, Appropriateness SYSTT. Treatment with anticancer drugs for advanced pancreatic cancer: a systematic review. BMC CANCER. 2023; 23(1):748. DOI:10.1186/s12885-023-11207-4. PMID:37573294. IF:3,400 (Q2/4D). Document type: Review.

-Sanchez A, Cajal TRY, Pineda M, Aguirre E, Grana B, Chirivella I, Balmana J, Brunet J, SEOM Hereditary Canc Working GRP, AEGH Hereditary Canc C. SEOM clinical guideline on heritable TP53-related cancer syndrome (2022). Clinical & Translational Oncology. 2023; 25(9). DOI:10.1007/s12094-023-03202-9. PMID:37133731. IF:2,800 (Q2/5D). Document type: Article.

-Sanfilippo R, Hindi N, Jurado JC, Blay JY, Lopez A, Italiano A, Alvarez R, Gutierrez A, Rincon I, Sangalli C, Aguiar JLP, Romero J, Morosi C, Sunyach MP, Fabbroni C, Romagosa C, Ranchere D, Dei AP, Casali PG, Martin J, Gronchi A. Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma A Nonrandomized Clinical Trial. JAMA Oncology. 2023; 9(5). DOI:10.1001/jamaoncol.2023.0056. PMID:36995731. IF:22,500 (Q1/1D). Document type: Article.

-Segura PP, Quintela NV, Garcia MM, Berron SD, Sarrio RG, Gomez JG, Castano AG, Martin LMN, Rubio OG, Losada EP. SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022). Clinical & Translational Oncology. 2023; 25(9). DOI:10.1007/s12094-023-03245-y. PMID:37540408. IF:2,800 (Q2/5D). Document type: Article.

-Serrano C, Álvarez R, Carrasco JA, Marquina G, Martínez J, Martínez V, Sala MÁ, Sebio A, Sevilla I, Martín J. SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022). Clinical & Translational Oncology. 2023; 25(9). DOI:10.1007/s12094-023-03177-7. PMID:37129716. IF:2,800 (Q2/5D). Document type: Article.

-Tibau A, Martínez MT, Ramos M, De La Cruz L, Santaballa A, O’Connor M, Martínez N, Moreno F, Fernández I, Virizuela JA, Alarcón J, de La Haba J, Sánchez P, Albacar CR, Bueno C, Kelly C, Casas M, Bezares S, Rosell L, Albanell J. Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial. Therapeutic Advances in Medical Oncology. 2023; 15:17588359221148921. DOI:10.1177/17588359221148921. PMID:36743520. IF:4,300 (Q2/3D). Document type: Article.

-Trilla L, Gámez A, Prado G, López R, Soriano V, Garicano F, Lecumberri MJ, Rodríguez de la Borbolla M, Majem M, Pérez E, González M, Oramas J, Magdaleno A, Fra J, Martín A, Corral M, Puértolas T, Ramos R, Dittmann A, Nanni P, Fresno JÁ, Espinosa E. Multi-omics Characterization of Response to PD-1 Inhibitors in Advanced Melanoma. Cancers. 2023; 15(17):4407. DOI:10.3390/cancers15174407. PMID:37686682. IF:4,500 (Q1/3D). Document type: Article.

-Trilla L, Gámez A, Prado G, López R, Zapater A, López E, Lumbreras MI, Soriano V, Garicano F, Lecumberri MJ, de la Borbolla MR, Majem M, Pérez E, González M, Oramas J, Magdaleno A, Fra J, Martín A, Corral M, Puértolas T, Ramos R, Vara J, Espinosa E. Sorting Transcriptomics Immune Information from Tumor Molecular Features Allows Prediction of Response to Anti-PD1 Therapy in Patients with Advanced Melanoma. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023; 24(1):801. DOI:10.3390/ijms24010801. PMID:36614248. IF:4,900 (Q1/3D). Document type: Article.

-Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, De Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL, ADAURA I. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. NEW ENGLAND JOURNAL OF MEDICINE. 2023; 389(2). DOI:10.1056/NEJMoa2304594. PMID:37272535. IF:96,200 (Q1/1D). Document type: Article.

-Tsutani Y, Goldman JW, Dacic S, Yatabe Y, Majem M, Huang X, Chen A, van der Gronde T, He J. Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2–IA3 EGFR-Mutated NSCLC: ADAURA2. Clinical Lung Cancer. 2023; 24(4). DOI:10.1016/j.cllc.2023.02.002. PMID:36872181. IF:3,300 (Q2/4D). Document type: Article.

-Valcarcel S, Gallego J, Jimenez P, Diez M, de Castro EM, Hernandez R, Arrazubi V, Custodio A, Cano JM, Montes AF, Macias I, Visa L, Calvo A, Tocino RV, Lago NM, Limon ML, Granja M, Gil M, Pimentel P, Macia L, Perez CH, Mangas M, Carnicero AM, Cerda P, Gonzalez LG, Navalon FG, Rambla MDM, Richard MM, Carmona A. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; 149(7). DOI:10.1007/s00432-022-04294-6. PMID:36042046. IF:2,700 (Q3/6D). Document type: Article.

-Vazquez JC, Antolin S, Ruiz M, Servitja S, Alba E, Barnadas A, Lluch A, Martin M, Rodriguez A, Sola I, Bonfill X, Urrutia G, Sanchez P. Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis. Clinical & Translational Oncology. 2023; 25(4). DOI:10.1007/s12094-022-02998-2. PMID:36417083. IF:2,800 (Q2/5D). Document type: Review.

-Vazquez JC, Pinero A, de Castro FJ, Lluch A, Martin M, Barnadas A, Alba E, Rodriguez A, Rojo F, Gimenez J, Sola I, Quintana MJ, Bonfill X, Urrutia G, Sanchez P. The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic review. Clinical & Translational Oncology. 2023; 25(2). DOI:10.1007/s12094-022-02953-1. PMID:36153763. IF:2,800 (Q2/5D). Document type: Review.

-Vidal J, Fernández MC, Casadevall D, García P, Páez D, Guix M, Alonso V, Cano MT, Santos C, Durán G, Elez E, Manzano JL, Garcia R, Ferreiro R, Losa F, Pineda E, Sastre J, Rivera F, Bellosillo B, Tabernero J, Aranda E, Salazar R, Montagut C, Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study. CLINICAL CANCER RESEARCH. 2023; 29(2). DOI:10.1158/1078-0432.CCR-22-1696. PMID:36074154. IF:10,400 (Q1/1D). Document type: Article.

-Wakelee H, Liberman M, Kato T, Tsuboi M, Lee S-H, Gao S, Chen K-N, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. NEW ENGLAND JOURNAL OF MEDICINE. 2023; 389(6). DOI:10.1056/NEJMoa2302983. PMID:37272513. IF:96,200 (Q1/1D). Document type: Article.

(JIF 2022)

• Adam R, Tibau A, Valiente CM, Seruga B, Ocana A, Amir E, Templeton AJ. Clinical benefit of cancer drugs approved in Switzerland 2010-2019. PLoS One. 2022; 17(6):e0268545. DOI:10.1371/journal.pone.0268545. PMID:35687539. IF:3,7 (Q2/4D). Document type: Article.
• Aguado E, Fuentes MJ, Gonzalo R, Alonso C, Ramón y Cajal T, Fisas D, Seoane A, Sánchez Á, Giralt J, Díez O, Gutiérrez S. Cell Senescence-Related Pathways Are Enriched in Breast Cancer Patients With Late Toxicity After Radiotherapy and Low Radiation-Induced Lymphocyte Apoptosis. Frontiers in Oncology. 2022; 12:825703. DOI:10.3389/fonc.2022.825703. PMID:35686103. IF:4,7 (Q2/4D). Document type: Article.
• Alserawan L, Anguera G, Atenza CZ, Lopez JS, Martinez L, Melia MR, Sullivan I, Joaquin AB, Tarruella MM, Vidal S. Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(20):12641. DOI:10.3390/ijms232012641. PMID:36293498. IF:5,6 (Q1/3D). Document type: Article.
• Aparicio J, Manrique A, Capdevila J, Boza FM, Galvan P, Richart P, Oliveres H, Paez D, Hernando J, Serrano S, Vera R, Hernandez X, Gallego RA, Riesco MC, de Albeniz XG, Maurel J. Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01). Clinical & Translational Oncology. 2022; 24(11). DOI:10.1007/s12094-022-02868-x. PMID:35761123. IF:3,4 (Q3/6D). Document type: Article.
• Argilés G, Valladares M, Viéitez JM, García B, Rodríguez M, Rivera F, Goldberg RM, Ciardiello F, Tabernero JM, Goldberg R, A, Tabernero J, Mulet N, Limón ML, Valladares M, Jiménez P, Vieitez JM, Grávalos C, García P, Santos C, Páez D, Tobeña M, Sastre J, García B, Benavides M, Aranda E, Cano MT, Loupakis F, Rguez M, Guillén C, Rivera MF, Safont J, Hiret S, et al. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial). EUROPEAN JOURNAL OF CANCER. 2022; 177. DOI:10.1016/j.ejca.2022.09.037. PMID:36335783. IF:8,4 (Q1/2D). Document type: Article.
• Arranz MJ, Salazar J, Bote V, Artigas A, Serra A, Trivino E, Roige J, Lombardia C, Cancino M, Hernandez M, Cendros M, Duran E, Maraver N, Hervas A. Pharmacogenetic Interventions Improve the Clinical Outcome of Treatment-Resistant Autistic Spectrum Disorder Sufferers. Pharmaceutics. 2022; 14(5):999. DOI:10.3390/pharmaceutics14050999. PMID:35631585. IF:5,4 (Q1/2D). Document type: Article.
• Arriola E, Gonzalez M, Domine M, De Castro J, Cobo M, Bernabe R, Navarro A, Sullivan I, Trigo JM, Mosquera J, Crama L, Isla D. Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis. Oncology And Therapy. 2022; 10(1). DOI:10.1007/s40487-021-00182-0. PMID:35032007. Document type: Review.
• Atenza CZ, Anguera G, Melia MR, De Lamo LA, Sullivan I, Joaquin AB, Lopez JS, Ortiz MA, Mulet M, Vidal S, Majem M. The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents. CANCER IMMUNOLOGY IMMUNOTHERAPY. 2022; 71(8). DOI:10.1007/s00262-021-03107-y. PMID:34984538. IF:5,8 (Q1/3D). Document type: Article.
• Bellmunt J, Valderrama BP, Puente J, Grande E, Bolós MV, Lainez N, Vázquez S, Maroto P, Climent MÁ, Garcia del Muro X, Arranz JÁ, Durán I. Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2022; 174:103683. DOI:10.1016/j.critrevonc.2022.103683. PMID:35439541. IF:6,2 (Q1/3D). Document type: Review.
• Bernabé R, Garrido P, García R, Palmero R, Artal Á, Bayona C, Rodríguez D, López M, Paredes A, Vicente D, Torres JMS, Majem M, Diz P, Gordo R, Coca M, de Castro J. Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program. Oncotarget. 2022; 13(1). DOI:10.18632/oncotarget.28244. Document type: Article.
• Blay JY, Hindi N, Bollard J, Aguiar S, Angel M, Araya B, Badilla R, Bernabeu D, Campos F, Caro CHS, Carvajal B, Montoya AC, Casavilca S, Castro V, Chacon M, Clara M, Collini P, Genoroso RC, Costa FD, Cuellar M, dei AP, Malagon HRD, Donati D, Dufresne A, Eriksson M, Farias M, Fernandez P, Frezza AM, Frisoni T, Garcia DY, Gelderblom H, Gouin F, Gomez MC, Gronchi A, et al. [Lopez-Pousa A]. SELNET clinical practice guidelines for soft tissue sarcoma and GIST. CANCER TREATMENT REVIEWS. 2022; 102:102312. DOI:10.1016/j.ctrv.2021.102312. PMID:34798363. IF:11,8 (Q1/1D). Document type: Review/Practice guideline.
• Blay JY, Palmerini E, Bollard J, Aguiar S, Angel M, Araya B, Badilla R, Bernabeu D, Campos F, Caro CHS, Montoya AC, Casavilca S, Castro V, Chacon M, Clara MA, Collini P, Genoroso RC, Costa FD, Cuellar M, Tos A, Malagon HRD, Donati DM, Dufresne A, Eriksson M, Farias M, Frezza AM, Frisoni T, Garcia DY, Gerderblom H, Gouin F, Gomez MC, Gronchi A, Haro J, et al. [Lopez-Pousa A]. SELNET clinical practice guidelines for bone sarcoma. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2022; 174:103685. DOI:10.1016/j.critrevonc.2022.103685. PMID:35460913. IF:6,2 (Q1/3D). Document type: Review/Practice guideline.
• Capdevila J, Gomez MA, Guillot M, Paez D, Pericay C, Safont MJ, Tarazona N, Vera R, Vidal J, Sastre J. SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021). Clinical & Translational Oncology. 2022; 24(4). DOI:10.1007/s12094-022-02816-9. PMID:35303269. IF:3,4 (Q3/6D). Document type: Article/Practice guideline.
• Casali PG, Blay JY, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brodowicz T, Buonadonna A, De Álava E, Dei AP, Del Muro XG, Dufresne A, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Frezza AM, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Haas R, Hassan AB, Hindi N, Hohenberger P, Joensuu H, et al. [Lopez-Pousa A]. Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up?. ANNALS OF ONCOLOGY. 2022; 33(1). DOI:10.1016/j.annonc.2021.09.005. PMID:34560242. IF:50,5 (Q1/1D). Document type: Article.
• Casarrubios M, Provencio M, Nadal E, Insa A, Garcia MD, Lazaro M, Domine M, Majem M, Rodriguez D, Martinez A, Carpeno JD, Cobo M, Vivanco GL, Del Barco E, Bernabe R, Vinolas N, Aranda IB, Massuti B, Sierra B, Martinez C, Fernandez I, Serna R, Romero A, Calvo V, Cruz A. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy. Journal for ImmunoTherapy of Cancer. 2022; 10(9):e005320. DOI:10.1136/jitc-2022-005320. PMID:36171009. IF:10,9 (Q1/2D). Document type: Article.
• Castellano D, Apolo AB, Porta C, Capdevila J, Viteri S, Rodriguez C, Martin L, Maroto P. Cabozantinib combination therapy for the treatment of solid tumors: a systematic review. Therapeutic Advances in Medical Oncology. 2022; 14:17588359221108691. DOI:10.1177/17588359221108691. PMID:35923927. IF:4,9 (Q2/4D). Document type: Review.
• Chow LQM, Barlesi F, Bertino EM, van den Bent MJ, Wakelee HA, Wen PY, Chiu CH, Orlov S, Chiari R, Majem M, McKeage M, Yu CJ, Garrido P, Hurtado FK, Arratia PC, Song YB, Branle F, Shi M, Kim DW. ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges. CLINICAL CANCER RESEARCH. 2022; 28(12). DOI:10.1158/1078-0432.CCR-21-1838. PMID:35091443. IF:11,5 (Q1/1D). Document type: Article.
• Climent MA, Font A, Duran I, Puente J, Mendez MJ, Saez MI, Lobera CS, Arija J, Gonzalez A, Sanchez A, Fita MJJ, Esteban E, Alonso T, Gonzalez BM, Maroto P, Lazaro M, Cassinello J, Perez B, Garcias C, Castellano D. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial. EUROPEAN JOURNAL OF CANCER. 2022; 175. DOI:10.1016/j.ejca.2022.08.002. PMID:36099670. IF:8,4 (Q1/2D). Document type: Article.
• Cortellini A, Ricciuti B, Vaz VR, Soldato D, Alessi JV, Dall’Olio FG, Banna GL, Muthuramalingam S, Chan S, Majem M, Piedra A, Lamberti G, Andrini E, Addeo A, Friedlaender A, Facchinetti F, Gorria T, Mezquita L, Hoton D, Valerie L, Nana FA, Artingstall J, Comins C, Di M, Caglio A, Cave J, McKenzie H, Newsom T, Evans JS, Tiseo M, D’Alessio A, Fulgenzi C, Besse B, Awad MM, Pinato DJ. Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. Journal for ImmunoTherapy of Cancer. 2022; 10(2):e004374. DOI:10.1136/jitc-2021-004374. PMID:35173031. IF:10,9 (Q1/2D). Document type: Article.
• Duarte V, Zaror C, Villanueva J, Andreo M, Dallaserra M, Salazar J, Pont A, Ferrer M. Oral Health-Related Quality of Life Changes in Patients with Dentofacial Deformities Class II and III after Orthognathic Surgery: A Systematic Review and Meta-Analysis. International Journal of Environmental Research and Public Health. 2022; 19(4):1940. DOI:10.3390/ijerph19041940. PMID:35206128. Document type: Article.
• Eggermont A, Ascierto PA, Khushalani NI, Schadendorf D, Boland G, Weber J, Lewis KD, Johnson D, Rivalland G, Khattak A, Majem M, Gogas H, Long GV, Currie SL, Chien D, Tagliaferri MA, Carlino MS, Diab A. PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. Future Oncology. 2022; 18(8). DOI:10.2217/fon-2021-1286. PMID:35073733. IF:3,3 (Q3/6D). Document type: Review.
• Francis KE, Kim SI, Friedlander M, Gebski V, Ray I, Clamp A, Penson RT, Oza A, Perri T, Huzarski T, Martin C, Cecere SC, Colombo N, Ataseven B, Fujiwara K, Sonke G, Vergote I, Pujade E, Kim J-W, Lee CK. The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer. ANNALS OF ONCOLOGY. 2022; 33(6). DOI:10.1016/j.annonc.2022.02.222. PMID:35219776. IF:50,5 (Q1/1D). Document type: Article.
• Garcia P, Saiz M, Mondejar R, Salazar J, Paez D, Borobia AM, Safont MJ, Garcia I, Colomer R, Garcia X, Herrero MJ, Lopez LA, Abad F. Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines. Clinical & Translational Oncology. 2022; 24(3). DOI:10.1007/s12094-021-02708-4. PMID:34773566. IF:3,4 (Q3/6D). Document type: Article.
• Gonzalez I, Rubio V, Medina J, Espana S, Mujika K, Majem M, Aguado C, Suarez M, Palacio I, Osterloh L, Martinez A, Garcia A. Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL). MELANOMA RESEARCH. 2022; 32(5). DOI:10.1097/CMR.0000000000000837. PMID:35762583. IF:2,2 (Q3/7D). Document type: Article.
• Hentrich MU, Bower M, Daugaard G, Dieing A, Bickel M, Berretta M, Lesmeister F, Jurinovic V, Stoehr A, Heinzelbecker J, Krznaric I, Dieckmann KP, Necchi A, Rey PM, Rockstroh JK, Brito M, Pfister D, Hoffmann C. Outcomes of men with HIV and germ cell cancer: Results from an international collaborative study. CANCER. 2022; 128(2). DOI:10.1002/cncr.33928. PMID:34592009. IF:6,2 (Q1/3D). Document type: Article.
• Herbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sanchez A, Dakhil S, Camidge DR, Winzer L, Soo Y, Cooper ZA, Kumar R, Bothos J, Aggarwal C, Martinez A. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. JOURNAL OF CLINICAL ONCOLOGY. 2022; 40(29):JCO.22.00227. DOI:10.1200/JCO.22.00227. PMID:35452273. IF:45,3 (Q1/1D). Document type: Article.
• Hernandez A, Munoz AM, Esteve A, Alameda F, Carrato C, Pineda E, Arpi O, Martinez M, Mallo M, Gut M, del Barco S, Gallego O, Dabad M, Mesia C, Bellosillo B, Domenech M, Vidal N, Aldecoa I, de la Iglesia N, Balana C. In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma. Scientific Reports. 2022; 12(1):14439. DOI:10.1038/s41598-022-18608-8. PMID:36002559. IF:4,6 (Q2/3D). Document type: Article.
• Hernandez MH, Bote V, Serra A, Cendros M, Salazar J, Mestres C, Guijarro S, Alvarez A, Lamborena C, Mendez I, Sanchez B, Hervas A, Arranz MJ. CES1 and SLC6A2 Genetic Variants As Predictors of Response To Methylphenidate in Autism Spectrum Disorders. Pharmacogenomics & Personalized Medicine. 2022; 15. DOI:10.2147/PGPM.S377210. PMID:36393977. IF:1,9 (Q4/9D). Document type: Article.
• Hidalgo S, Carrillo J, Moura DS, Stacchiotti S, López A, Redondo A, Italiano A, Gutiérrez A, Grignani G, Hindi N, López J-A, Muro XGD, Trufero JM, Palmerini E, García AS, Bernabeu D, Le A, Casali PG, Blay J-Y, Cruz J, Martin J. Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib. Cancers. 2022; 14(17):4186. DOI:10.3390/cancers14174186. PMID:36077723. IF:5,2 (Q2/3D). Document type: Article.
• Hwang TJ, Kesselheim AS, Tibau A, Lee CC, Vokinger KN. Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia. JCO Oncology Practice. 2022; 18(9). DOI:10.1200/OP.21.00909. PMID:35731996. IF:4 (Q2/4D). Document type: Article.
• Hwang TJ, Trinh QD, Tibau A, Vokinger KN. Reforms to accelerated approval of new medicines: long overdue. LANCET. 2022; 400(10349). DOI:10.1016/S0140-6736(22)01276-4. PMID:35835129. IF:168,9 (Q1/1D). Document type: Letter.
• Isla D, Majem M. A Paradigm Shift for Resectable Non-Small Cell Lung Cancer. ARCHIVOS DE BRONCONEUMOLOGIA. 2022; 58(12). DOI:10.1016/j.arbres.2022.04.004. PMID:35595655. IF:8 (Q1/2D). Document type: Editorial material.
• Jacob J, Gene E, Escalada X, Villamor A, Hernandez R, Miro O. Quality of interpersonal relations among emergency medical staff in Catalonia and differences in hospital and prehospital settings: a survey study. Emergencias. 2022; 34(5)PMID:36217936. IF:5,5 (Q1/2D). Document type: Editorial material.
• Kuemmel S, Campone M, Loirat D, Lopez RL, Beck JT, De Laurentiis M, Im SA, Kim SB, Kwong A, Steger GG, Adelantado EZ, Duhoux FP, Greil R, Kuter I, Lu YS, Tibau A, Ozguroglu M, Scholz CW, Singer CF, Vega E, Wimberger P, Zamagni C, Couillebault XM, Fan LQ, Guerreiro N, Mataraza J, Sand J, Chan A. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. CLINICAL CANCER RESEARCH. 2022; 28(1). DOI:10.1158/1078-0432.CCR-20-3955. PMID:34615719. IF:11,5 (Q1/1D). Document type: Article.
• Lindskog M, Laurell A, Kjellman A, Melichar B, Rey PM, Zielinski H, Villacampa F, Bigot P, Zoltan B, Parikh O, Alba DV, Jellvert D, Flasko T, Gallardo E, Caparros MJR, Purkalne G, Suenaert P, Karlsson A, Ljungberg B. Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study. European Urology Open Science. 2022; 40. DOI:10.1016/j.euros.2022.03.012. PMID:35638086. IF:2,5 (Q3/6D). Document type: Article.
• Majem M, Alvarez R, Ortega AL, de Alda LR, Gordo R, Garcia JF, Ivanova Y, Gonzalez A, San Cristobal RS, Rojo F. Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non-small cell lung cancer in Spain. Global & Regional Health Technology Assessment. 2022; 9. DOI:10.33393/grhta.2022.2449. PMID:36628311. IF:0,5 (Q4/10D). Document type: Article.
• Majem M, de las Penas R, Virizuela JA, Cabezon L, Cruz P, Lopez R, Mendez M, Mondejar R, Munoz MD, Escobar Y. SEOM clinical guideline emesis (2021). Clinical & Translational Oncology. 2022; 24(4). DOI:10.1007/s12094-022-02802-1. PMID:35347571. IF:3,4 (Q3/6D). Document type: Article/Practice guideline.
• Majem M, Goldman JW, John T, Grohe C, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Li SQ, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Atagi S, Zeng LM, Kulkarni D, Medic N, Tsuboi M, Herbst RS, Wu YL. Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. CLINICAL CANCER RESEARCH. 2022; 28(11). DOI:10.1158/1078-0432.CCR-21-3530. PMID:35012927. IF:11,5 (Q1/1D). Document type: Article.
• Manrique A, Salazar J, Arranz MJ, Bague S, Orellana R, Lopez A, Cerda P, Gracia I, Majercakova K, Peiro A, Trullols L, Fernandez M, Valverde S, Quintana MJ, Bell O, Artigas A, Sebio A. Pharmacogenetic Profiling in High-Risk Soft Tissue Sarcomas Treated with Neoadjuvant Chemotherapy. Journal of Personalized Medicine. 2022; 12(4):618. DOI:10.3390/jpm12040618. PMID:35455734. Document type: Article.
• Maroto P, Porta C, Capdevila J, Apolo AB, Viteri S, Rodriguez C, Martin L, Castellano D. Cabozantinib for the treatment of solid tumors: a systematic review. Therapeutic Advances in Medical Oncology. 2022; 14:17588359221107112. DOI:10.1177/17588359221107112. PMID:35847482. IF:4,9 (Q2/4D). Document type: Review.
• Martin J, Redondo A, Moura DS, Valverde C, Morales JM, Lopez A, Martinez J, Gutierrez A, Díaz R, Luna P, Martinez V, Marcilla D, Arribas I, Ledesma P, Lopez JA, Di D, Zamora J, Hindi N. A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors. Nature Communications. 2022; 13(1):6278. DOI:10.1038/s41467-022-33975-6. PMID:36271011. IF:16,6 (Q1/1D). Document type: Article.
• Molto C, Tibau A, Bujosa A, Tapia JC, Mittal A, Tamimi F, Amir E. Association between control group therapy and magnitude of clinical benefit of cancer drugs. Scientific Reports. 2022; 12(1):21342. DOI:10.1038/s41598-022-25983-9. PMID:36494465. IF:4,6 (Q2/3D). Document type: Article.
• Mulet M, Osuna R, Zamora C, Porcel JM, Nieto JC, Perea L, Pajares V, Munoz AM, Calvo N, Sorolla MA, Vidal S. Influence of Malignant Pleural Fluid from Lung Adenocarcinoma Patients on Neutrophil Response. Cancers. 2022; 14(10):2529. DOI:10.3390/cancers14102529. PMID:35626131. IF:5,2 (Q2/3D). Document type: Article.
• Palassini E, Mir O, Grignani G, Vincenzi B, Gelderblom H, Sebio A, Valverde C, Baldi GG, Brunello A, Cardellino GG, Marrari A, Badalamenti G, Martin J, Ferraresi V, Libertini M, Turano S, Gataa I, Collini P, Dei AP, Gennaro M, Bini F, Provenzano S, Lo Vullo S, Mariani L, Le A, Casali PG. Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses. BREAST CANCER RESEARCH AND TREATMENT. 2022; 192(3). DOI:10.1007/s10549-022-06524-4. PMID:35150367. IF:3,8 (Q2/5D). Document type: Article.
• Pasquali S, Palmerini E, Quagliuolo V, Martin J, Lopez A, Grignani G, Brunello A, Blay JY, Tendero O, Diaz R, Ferraresi V, Lugowska I, Infante G, Braglia L, Merlo DF, Fontana V, Marchesi E, Donati DM, Palassini E, Bianchi G, Marrari A, Morosi C, Stacchiotti S, Bague S, Coindre JM, Dei AP, Picci P, Bruzzi P, Miceli R, Casali PG, Gronchi A. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial. CANCER. 2022; 128(1). DOI:10.1002/cncr.33895. PMID:34643947. IF:6,2 (Q1/3D). Document type: Article.
• Pena L, Ercibengoa M, Mercadillo F, Gómez D, Inglada L, Santos M, Lanillos J, Gutiérrez D, Hernández A, Carbonell P, Letón R, Robledo M, Rodríguez C, Perea J, Urioste M, Alonso MÁ, Andrés R, Arévalo S, del Mar M, Balmaña J, Beristain E, Blanco I, Boronat M, Brunet J, Cózar MV, del Campo M, Díaz A, Gabau E, Barcina MJ, González M, Guitart M, Hernán I, et al. [Lasa A, Ramon y Cajal T]. Considerations on diagnosis and surveillance measures of PTEN hamartoma tumor syndrome: clinical and genetic study in a series of Spanish patients. Orphanet Journal of Rare Diseases. 2022; 17(1):85. DOI:10.1186/s13023-021-02079-7. PMID:35227301. IF:3,7 (Q2/4D). Document type: Article.
• Peters S, Pujol J-L, Dafni U, Dómine M, Popat S, Reck M, Andrade J, Becker A, Moro D, Curioni A, Molinier O, Nackaerts K, Insa A, Gervais R, López G, Madelaine J, Mazieres J, Faehling M, Griesinger F, Majem M, González JL, Provencio M, Vervita K, Roschitzki H, Ruepp B, Mitchell P, Stahel RA, Le C, De Ruysscher D, Stahel R, Hiltbrunner A, Pardo M, et al. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. ANNALS OF ONCOLOGY. 2022; 33(1). DOI:10.1016/j.annonc.2021.09.011. PMID:34562610. IF:50,5 (Q1/1D). Document type: Article.
• Pinto Á, Reig O, Iglesias C, Gallardo E, García X, Alonso T, Anguera G, Suárez C, Muñoz J, Villalobos L, Rodríguez Á, Lainez N, Martínez E, Campayo M, Velastegui A, Rodriguez A, Villa JC, Méndez MJ, Rubio G, García I, Capdevila L, Lambea J, Vázquez S, Fernández O, Hernando S, Cerezo S, Santander C, García R, Zambrana F, González A, Lazaro M, Castellano D, Chirivella I, Anido U, Viana A, García A, Sotelo M, Arévalo MG, García J, Hernández C, Bolós MV, Llinares J, Climent MA. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study. Clinical Genitourinary Cancer. 2022; 20(1). DOI:10.1016/j.clgc.2021.09.006. PMID:34789409. IF:3,2 (Q2/4D). Document type: Article.
• Provencio M, Rodriguez D, Ortega AL, Serrano G, Aguado C, Franco F, Gutierrez V, Vivanco GL, Guirado M, Benitez G, Estival A, Calvo V, Jimenez B, Arasanz H, Coves J, Majem M, Massuti B, Vazquez S, Juan O, Collazo A, Gozalvez CL, Del Barco E, Rosero A, Bosch J, Moreno MA, Mielgo X, Villa JC, Lopez A, Cordoba JF, Aparisi FD, Zafra M, Mosquera J, Altozano JP, Nadal E, Catot S, Balsalobre J, De Portugal T, Martin P, De Juan SC, Cobo M. Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study. Translational Lung Cancer Research. 2022; 11(1). DOI:10.21037/tlcr-21-504. PMID:35242627. IF:4 (Q2/4D). Document type: Article.
• Provencio M, Serna R, Nadal E, Insa A, García MR, Casal J, Dómine M, Majem M, Rodríguez D, Martínez A, De Castro J, Cobo M, López G, Del Barco E, Bernabé R, Viñolas N, Barneto I, Viteri S, Pereira E, Royuela A, Calvo V, Martín J, García F, Casarrubios M, Franco F, Sánchez E, Massuti B, Cruz A, Romero A. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). JOURNAL OF CLINICAL ONCOLOGY. 2022; 71:35576508. DOI:10.1200/JCO.21.02660. PMID:35576508. IF:45,3 (Q1/1D). Document type: Article.
• Remon J, Bernabe R, Diz P, Felip E, Gonzalez JL, Lazaro M, Mielgo X, Sanchez A, Sullivan I, Massutti B. SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021). Clinical & Translational Oncology. 2022; 24(4)DOI:10.1007/s12094-022-02788-w. PMID:35122634. IF:3,4 (Q3/6D). Document type: Article/Practice guideline.
• Riudavets M, Auclin E, Mosteiro M, Dempsey N, Majem M, Lobefaro R, López R, Bosch J, Pilotto S, Escalera E, Tagliamento M, Mosquera J, Zalcman G, Aboubakar F, Ponce S, Dal A, Spotti M, Mielgo X, Mussat E, Reyes R, Benítez J-C, Lupinacci L, Duchemann B, De Giglio A, Blaquier J, Audigier C, Scheffler M, Nadal E, Lopes G, Signorelli D, Garcia R, Menis J, Bluthgen V, Campayo M, Recondo G, Besse B, Planchard D, Mezquita L. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations. EUROPEAN JOURNAL OF CANCER. 2022; 167. DOI:10.1016/j.ejca.2022.02.014. PMID:35307254. IF:8,4 (Q1/2D). Document type: Article.
• Rodríguez F, Caruana P, De la Fuente N, Español P, Gámez M, Balart J, Llurba E, RAMON N, Ruiz R, Martín C, Corchero JL, Céspedes MV. Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges. 2022; 12(6):784. DOI:10.3390/biom12060784. PMID:35740909. IF:5,5 (Q1/3D). Document type: Review.
• Sala R, Rioja E, Serna N, Sanchez L, Alamo P, Alba L, Casanova I, Lopez A, Unzueta U, Cespedes MV, Vazquez E, Villaverde A, Mangues R. GSDMD-dependent pyroptotic induction by a multivalent CXCR4-targeted nanotoxin blocks colorectal cancer metastases. DRUG DELIVERY. 2022; 29(1). DOI:10.1080/10717544.2022.2069302. PMID:35532120. IF:6 (Q1/2D). Document type: Article.
• Salvador J, Moreno F, Rodriguez CA, Galve E, Hernando C, Ciruelos EM, Vidal M, Jiménez B, De la Cruz L, Martínez N, Villanueva R, de Toro R, Anton A, Alvarez IM, Gavila J, Quiroga V, Vicente E, De la Haba J, Gonzalez S, Diaz N, Barnadas A, Cantos Sanchez de Ibargüen B, Delgado JI, Bellet M, de Casa S, Gimeno A, Martin M. Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial. BREAST. 2022; 66. DOI:10.1016/j.breast.2022.09.006. PMID:36206609. IF:3,9 (Q1/3D). Document type: Article.
• Sanchez A, Roos VH, Navarro M, Pineda M, Caballol B, Moreno L, Carballal S, Rodriguez L, Cajal TRY, Llort G, Pinol V, Lopez A, Salces I, Pico MD, Rivas L, Bujanda L, Garzon M, Pizarro A, de Castro EM, Lopez MJ, Poves C, Garau C, Rodriguez D, Herraiz M, Alvarez C, Dacal A, Carrillo M, Cid L, Ponce M, Barreiro E, Saperas E, Aguirre E, Romero C, Bastiaansen B, Gonzalez M, Morales B, Ocana T, Rivero L, Jung G, Bessa X, Cubiella J, Jover R, Rodriguez F, Balmana J, Brunet J, Castells A, Dekker E, Capella G, Serra M, Moreira L, Pellise M, Balaguer F. Quality of Colonoscopy Is Associated With Adenoma Detection and Postcolonoscopy Colorectal Cancer Prevention in Lynch Syndrome. Clinical Gastroenterology and Hepatology. 2022; 20(3). DOI:10.1016/j.cgh.2020.11.002. PMID:33157315. IF:12,6 (Q1/1D). Document type: Article.
• Serda PC, Teres R, Sebio A, Bague S, Orellana R, Moreno ME, Riba M, Lopez A. Single-Center Experience with Trabectedin for the Treatment of Non-L-sarcomas. ADVANCES IN THERAPY. 2022; 39(4). DOI:10.1007/s12325-022-02051-2. PMID:35129790. IF:3,8 (Q2/4D). Document type: Article.
• Sooy RA, Han JY, Dafni U, Cho BC, Yeo CM, Nadal E, Carcereny E, de Castro J, Sala MA, Bernabee R, Coate L, Pulla MP, Campelo RG, Cuffe S, Hashemi SMS, Fruh M, Massuti B, Garcia J, Domine M, Majem M, Sanchez JM, Britschgi C, Pless M, Dimopoulou G, Roschitzki H, Ruepp B, Rosell R, Stahel RA, Peters S. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. ANNALS OF ONCOLOGY. 2022; 33(2). DOI:10.1016/j.annonc.2021.11.010. PMID:34839016. IF:50,5 (Q1/1D). Document type: Article.
• Tapia JC, Gavira J, Lopez A, Llobera L, Pallise O, Marsal I, Cochs A, Ponce OJ, Riudavets M, Gich I, Barnadas A, Majem M. Ninety-day mortality and clinical outcomes of patients with solid tumours and COVID-19 infection during the first pandemic outbreak in Catalonia, Spain: A multicentre retrospective study. INTERNATIONAL JOURNAL OF CANCER. 2022; 150(8). DOI:10.1002/ijc.33909. PMID:34921732. IF:6,4 (Q1/3D). Document type: Article.
• Vazquez JC, Pinero A, de Castro FJ, Lluch A, Martin M, Barnadas A, Alba E, Rodriguez A, Rojo F, Gimenez J, Sola I, Quintana MJ, Bonfill X, Urrutia G, Sanchez P. The value of sentinel lymph-node biopsy after neoadjuvant therapy: an overview. Clinical & Translational Oncology. 2022; 24(9). DOI:10.1007/s12094-022-02824-9. PMID:35414152. IF:3,4 (Q3/6D). Document type: Article.
• Wu YL, John T, Grohe C, Majem M, Goldman JW, Kim SW, Kato T, Laktionov K, Vu HV, Wang ZJ, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng LM, Atasoy A, Herbst RS, Tsuboi M. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. Journal of Thoracic Oncology. 2022; 17(3). DOI:10.1016/j.jtho.2021.10.014. PMID:34740861. IF:20,4 (Q1/1D). Document type: Article.

• Castillo S, Muñoz S, Arcocha A, López-Vilaró L, Sullivan I, Aldeguer E, Rodríguez S, Moya I, Viteri S, Cardona AF, Palmero R, Sainz C, Mesa-Guzmán M, Lozano MD, Aguilar-Hernández A, Martínez-Bueno A, González-Cao M, Gonzalvo E, Leenders WPJ, Rosell R, et al. Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer. Molecular Oncology. 2021;15(2):350-363. DOI:10.1002/1878-0261.12861. PMID: 33236532. IF:7,449.
• Alvarez F, Jimenez P, Carmona A, Arrazubi V, Hernandez R, Cano JM, Custodio A, Pijaume CP, Aguado G, Lago NM, Canovas MS, Lavin DC, Visa L, Martinez A, Arias A, Lopez F, Limon ML, Tocino RV, Montes AF, Alsina M, Pimentel P, Reguera P, Carnicero AM, Ramchandani A, Granja M, Azkarate A, Richard MM, Serra O, Perez CH, Hurtado A, Gil A, Sauri T, et al. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry. Gastric Cancer. 2021; 24(4). DOI:10.1007/s10120-021-01169-6. PMID:33651195. IF:7,701.
• Aparicio J, García Del Muro X, Maroto P, Terrasa J, Castellano D, Bastús R, Gumà J, Sagastibeltza N, Durán I, Ochenduszko S, Meana JA, García-Sánchez J, Arranz JA, Gironés R, Germà JR. Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group. Clinical & Translational Oncology. 2021;23(1):58-64. DOI:10.1007/s12094-020-02393-9. PMID: 32462393. IF:3,340.
• Arranz MJ, Gallego C, Martin A, Soler J, Elices M, Dominguez E, Salazar J, Vega D, Briones L, Pascual JC. A genome-wide methylation study reveals X chromosome and childhood trauma methylation alterations associated with borderline personality disorder. Translational Psychiatry. 2021; 11(1):5. DOI:10.1038/s41398-020-01139-z. PMID:33414392. IF:7,989.
• Arranz MJ, Salazar J, Hernandez MH. Pharmacogenetics of antipsychotics: Clinical utility and implementation. BEHAVIOURAL BRAIN RESEARCH. 2021; 401:113058. DOI:10.1016/j.bbr.2020.113058. PMID:33316324. IF:3,352.
• Bancroft EK, Page EC, Brook MN, Thomas S, Taylor N, Pope J, McHugh J, Jones AB, Karlsson Q, Merson S, Ong KR, Hoffman J, Huber C, Maehle L, Grindedal EM, Stormorken A, Evans DG, Rothwell J, Lalloo F, Brady AF, Bartlett M, Snape K, Hanson H, James P, McKinley J, Mascarenhas L, Syngal S, Ukaegbu C, Side L, Thomas T, Barwell J, et al. [Cajal TRY]. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. LANCET ONCOLOGY. 2021; 22(11). DOI:10.1016/S1470-2045(21)00522-2. PMID:34678156. IF:54,433.
• Bellmunt J, Esteban E, del Muro XG, Sepulveda JM, Maroto P, Gallardo E, del Alba AG, Etxaniz O, Guix M, Larriba JLG, Arranz JA, Redrado M, Calvo A. Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era. European Urology Oncology. 2021; 4(3). DOI:10.1016/j.euo.2019.07.014. PMID:31477526. IF:8,208.
• Bjartell A, Lumen N, Maroto P, Paiss T, Gomez F, Birtle A, Kramer G, Kalinka E, Spaeth D, Feyerabend S, Matveev V, Lefresne F, Lukac M, Wapenaar R, Costa L, Chowdhury S. Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry. Targeted Oncology. 2021; 16(3). DOI:10.1007/s11523-021-00807-4. PMID:33826036. IF:4,864.
• Blackhall F, Jao K, Greillier L, Cho BC, Penkov K, Reguart N, Majem M, Nackaerts K, Syrigos K, Hansen K, Schuette W, Cetnar J, Cappuzzo F, Okamoto I, Erman M, Langer SW, Kato T, Groen H, Sun ZW, Luo Y, Tanwani P, Caffrey L, Komarnitsky P, Reinmuth N. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. Journal of Thoracic Oncology. 2021; 16(9). DOI:10.1016/j.jtho.2021.02.009. PMID:33607312. IF:20,121.
• Caamano AG, Vicente A, Maroto P, Antolin AR, Sanz J, Gonzalez M, Climent MA. Management of Localized Muscle-Invasive Bladder Cancer from a Multidisciplinary Perspective: Current Position of the Spanish Oncology Genitourinary (SOGUG) Working Group. Current Oncology. 2021; 28(6). DOI:10.3390/curroncol28060428. PMID:34940067. IF:3,109.
• Canto E, Faba OR, Zamora C, Mulet M, Garcia MS, Palomino A, Anguera G, Breda A, Maroto P, Vidal S. Immunological Status of Bladder Cancer Patients Based on Urine Leukocyte Composition at Radical Cystectomy. Biomedicines. 2021; 9(9):1125. DOI:10.3390/biomedicines9091125. PMID:34572311. IF:4,757.
• Casarrubios M, Cruz A, Nadal E, Insa A, Campelo MDG, Lazaro M, Domine M, Majem M, Rodriguez D, Martinez A, de Castro J, Cobo M, Lopez G, Del Barco E, Caro RB, Vinolas N, Aranda IB, Viteri S, Massuti B, Barquin M, Laza R, Sierra B, Parra ER, Sanchez B, Rocha P, Kadara H, Wistuba II, Romero A, Calvo V, Provencio M. Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy. CLINICAL CANCER RESEARCH. 2021; 27(21). DOI:10.1158/1078-0432.CCR-21-1200. PMID:34376534. IF:13,801.
• Cortellini A, Ricciuti B, Facchinetti F, Alessi JVM, Venkatraman D, Dall’Olio FG, Cravero P, Vaz VR, Ottaviani D, Majem M, Piedra A, Sullivan I, Lee KA, Lamberti G, Hussain N, Clark J, Bolina A, Barba A, Benitez JC, Gorria T, Mezquita L, Hoton D, Nana FA, Besse B, Awad MM, Pinato DJ. Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. ANNALS OF ONCOLOGY. 2021; 32(11). DOI:10.1016/j.annonc.2021.08.1744. PMID:34400292. IF:51,769.
• Dabush DR, Shepshelovich D, Shochat T, Tibau A, Amir E, Goldvaser H. The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysis. CANCER TREATMENT REVIEWS. 2021; 100:102293. DOI:10.1016/j.ctrv.2021.102293. PMID:34543860. IF:13,608.
• del Alba AG, Mendez MJ, Vazquez S, Castro E, Climent MA, Gallardo E, Gonzalez E, Lorente D, Maroto JP, Arranz JA. SEOM clinical guidelines for the treatment of advanced prostate cancer (2020). Clinical & Translational Oncology. 2021; 23(5). DOI:10.1007/s12094-021-02561-5. PMID:33625671. IF:3,340.
• Elez E, Ayala F, Felip E, Campelo RG, Carbonero RG, Donas JG, del Alba AG, Flores EG, Hidalgo J, Isla D, Majem M, Lescure AR, Safont MJ, Santaballa A, Villacampa G, Vera R, Garrido P. Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM). ESMO Open. 2021; 6(2):100048. DOI:10.1016/j.esmoop.2021.100048. PMID:33556897. IF:6,883.
• Escobar C, Barrios V, Lip GYH, Amin AN, Auladell A, Santero M, Salazar J, Requeijo C. Effectiveness and Safety of Dabigatran Compared to Vitamin K Antagonists in Non-Asian Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis. CLINICAL DRUG INVESTIGATION. 2021; 41(11). DOI:10.1007/s40261-021-01091-w. PMID:34643934. IF:3,580.
• Escuin D, Lopez L, Mora J, Bell O, Moral A, Perez I, Arqueros C, Garcia B, Cajal TRY, Lerma E, Barnadas A. Circulating microRNAs in Early Breast Cancer Patients and Its Association With Lymph Node Metastases. Frontiers in Oncology. 2021; 11:627811. DOI:10.3389/fonc.2021.627811. PMID:34513655. IF:5,738.
• Esteve A, Alameda F, Carrato C, Pineda E, Arpi O, Martinez M, Mallo M, Gut M, Dabad M, Tortosa A, Del Barco S, Capellades J, Puig J, Gallego O, Pujol T, Oleaga L, Gil M, de Quintana C, Valduvieco I, Martinez A, Bellosillo B, Munoz AM, Esteve A, Domenech M, Camins A, Craven J, Villa S, Marruecos J, Domenech S, de la Iglesia N, et al. [Bagué S]. RNA sequencing and Immunohistochemistry Reveal ZFN7 as a Stronger Marker of Survival than Molecular Subtypes in G-CIMP-negative Glioblastoma. CLINICAL CANCER RESEARCH. 2021; 27(2). DOI:10.1158/1078-0432.CCR-20-2141. PMID:33106291. IF:13,801.
• Garrido P, Paz L, Majem M, Moran T, Trigo JM, Bosch J, Garcia R, Gonzalez JL, Sanchez JM, Isla D, Vinolas N, Camps C, Insa A, Juan O, Massuti B, Paredes A, Artal A, Lopez M, Palacios J, Felip E. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. Cancer Medicine. 2021; 10(17). DOI:10.1002/cam4.4135. PMID:34296539. IF:4,711.
• Gil MJ, Bellet M, Bergamino M, Morales S, Barnadas A, Manso L, Saura C, Fernandez A, Garcia E, Martinez N, Mele M, Villagrasa P, Celiz P, Martin XP, Ciruelos E, Pernas S. Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study. Frontiers in Oncology. 2021; 11:645026. DOI:10.3389/fonc.2021.645026. PMID:34307126. IF:5,738.
• Gimenez A, Bracht J, Garcia JJ, Jordana N, Garcia B, Garzon M, Mayo C, Viteri S, Martinez A, Aguilar A, Sullivan IG, Johnson E, Huang CY, Gerlach JL, Warren S, Beechem JM, Teixido C, Rosell R, Reguart N, Molina MA. Multiplex Detection of Clinically Relevant Mutations in Liquid Biopsies of Cancer Patients Using a Hybridization-Based Platform. CLINICAL CHEMISTRY. 2021; 67(3). DOI:10.1093/clinchem/hvaa248. PMID:33439966. IF:12,167.
• Gronchi A, Miah AB, DeiTos AP, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Blay JY, Bolle S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brennan B, Brodowicz T, Buonadonna A, DeAlava E, Del Muro XG, Dufresne A, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Frezza AM, Gasperoni S, Gelderblom H, Gouin F, et al. [Lopez A]. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANNALS OF ONCOLOGY. 2021; 32(11). DOI:10.1016/j.annonc.2021.07.006. PMID:34303806. IF:51,769.
• Guigay J, Auperin A, Fayette J, Saada E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R, Gallego O, López A, Vazquez S. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. LANCET ONCOLOGY. 2021; 22(4). DOI:10.1016/S1470-2045(20)30755-5. PMID:33684370. IF:54,433.
• Hitt R, Iglesias L, Lopez-Pousa A, Berrocal-Jaime A, Grau JJ, Garcia-Giron C, Martínez-Trufero J, Guix M, Lambea-Sorrosal J, Del Barco-Morillo E, Leon-Vintro X, Cunquero-Tomas AJ, Baste N, Ocaña A, Cruz-Hernández JJ; the Spanish Head and Neck Cancer Cooperative Group (TTCC). Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial. Clinical & Translational Oncology. 2021;23(4):764-772. DOI:10.1007/s12094-020-02467-8. PMID: 32797376. IF:3,340.
• Iglesias P, Peiro I, Biagetti B, Paja M, Cobo DA, Gomez CG, Mateu M, Genua I, Majem M, Riudavets M, Gavira J, Lamas C, Pombo AF, Guerrero F, Villabona C, Agricola JMC, Webb SM, Diez JJ. Immunotherapy-induced isolated ACTH deficiency in cancer therapy. ENDOCRINE-RELATED CANCER. 2021; 28(12). DOI:10.1530/ERC-21-0228. PMID:34609950. IF:5,900.
• Isla D, de Castro J, García-Campelo R, Majem M, Vicente D, Juan-Vidal O. Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus. Clinical & Translational Oncology. 2021;23(7):1304-1313. DOI:10.1007/s12094-020-02518-0. PMID: 33210237. IF:3,340.
• Jimenez P, Carmona A, Martinez A, Alsina M, Custodio A, Serra O, Lavin DC, Limon ML, Sauri T, Lopez F, Visa L, Granja M, Lago NM, Arrazubi V, Tocino RV, Hernandez R, Aguado G, Cano JM, Carnicero AM, Mangas M, Pimentel P, Montes AF, Declara IM, Longo F, Ramchandani A, Richard MM, Hurtado A, Azkarate A, Perez CH, Serrano R, Gallego J. External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry. Therapeutic Advances in Medical Oncology. 2021; 13:17588359211019672. DOI:10.1177/17588359211019672. PMID:34211587. IF:5,485.
• Jimenez P, Pacheco V, Cebria A, Galvez F, Obispo B, Paez D, Quilez A, Quintanar T, Ramchandani A, Remon J, Rogado J, Sanchez DA, Sanchez M, Sanz E, Sesma A, Tarazona N, Cotes A, Gonzalez E, Bosch J, Fernandez A, Felip E, Vera R, Rodriguez A, Elez E. Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM). ESMO Open. 2021; 6(4):100215. DOI:10.1016/j.esmoop.2021.100215. PMID:34325108. IF:6,883.
• Jimenez-Fonseca P, Carmona-Bayonas A, Martínez de Castro E, Custodio A, Pericay Pijaume C, Hernandez R, Aguado G, Castro Unanua N, Cano JM, López F, Garrido M, Fernández Montes A, Visa L, Sánchez Cánovas M, Limón ML, Martínez Lago N, Pimentel P, Hurtado A, Azkárate A, Longo F, Diez M, Arias-Martinez A, Sauri T, et al. [Martín Richard M]. External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit? Gastric Cancer. 2021 Mar;24(2):445-456. DOI:10.1007/s10120-020-01116-x. PMID: 32970266; IF:7,701.
• Kim SJ, Lubinski J, Huzarski T, Moller P, Armel S, Karlan BY, Senter L, Eisen A, Foulkes WD, Singer CF, Tung N, Bordeleau L, Neuhausen SL, Olopade OI, Eng C, Weitzel JN, Fruscio R, Narod SA, Kotsopoulos J, Cajal TR, Trister R. Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. 2021; 30(11). DOI:10.1158/1055-9965.EPI-21-0296. PMID:34426412. IF:4,090.
• Laza R, Cruz A, Nadal E, Insa A, Garcia MD, Huidobro G, Domine M, Majem M, Rodriguez D, Martinez A, Carpeno JD, Cobo M, Vivanco GL, Del Barco E, Caro RB, Vinolas N, Aranda IB, Viteri S, Massuti B, Casarrubios M, Sierra B, Tarin C, Garcia A, Haymaker C, Wistuba II, Romero A, Franco F, Provencio M. Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. Clinical and Translational Medicine. 2021; 11(7):e491. DOI:10.1002/ctm2.491. PMID:34323406. IF:8,554.
• Lewis JH, Gelderblom H, van de Sande M, Stacchiotti S, Healey JH, Tap WD, Wagner AJ, Lopez-Pousa A, Druta M, Lin CC, Baba HA, Choi Y, Wang Q, Shuster DE, Bauer S. Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors. Oncologist. 2021;26(5):e863-e873. DOI:10.1002/onco.13629. PMID: 33289960. IF:5,837.
• Majem M, Cobo M, Isla D, Marquez D, Rodriguez D, Casal J, Moran T, Bernabe R, Perez D, Ruiz P, Arroyo MM, Paz L. PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis. Journal of Clinical Medicine. 2021; 10(7):1365. DOI:10.3390/jcm10071365. PMID:33810441. IF:4,964.
• Majem M, Manzano JL, Marquez I, Mujika K, Munoz E, Perez E, de la Cruz L, Espinosa E, Gonzalez M, Berrocal A. SEOM clinical guideline for the management of cutaneous melanoma (2020). Clinical & Translational Oncology. 2021; 23(5). DOI:10.1007/s12094-020-02539-9. PMID:33651321. IF:3,340.
• Majem M, Sullivan I, Viteri S, Lopez G, Cobo M, Sanchez JM, Garcia J, Garde J, Sampayo M, Martrat G, Malfettone A, Karachaliou N, Molina MA, Rosell R. First-line osimertinib in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met. EUROPEAN JOURNAL OF CANCER. 2021; 159. DOI:10.1016/j.ejca.2021.09.039. PMID:34763195. IF:10,002.
• Maroto P, del Muro XG, Valverde C, Pinto A, Sanchez A, Guma J, Alonso T, del Prado PM, Vazquez S, Mellado B, Aparicio J, Fernandez A, Girones R, Terrasa J. Incidence and clinical pattern of contralateral synchronous and metachronous germ cell testicular cancer. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. 2021; 39(2). DOI:10.1016/j.urolonc.2020.11.004. PMID:33189529. IF:2,954.
• Martin J, Lopez M, Moura DS, Ramos R, Collini P, Romagosa C, Bague S, Renne SL, Barisella M, Velasco V, Coindre JM, Lopez D, Dopazo J, Gambarotti M, Braglia L, Merlo DF, Palmerini E, Stacchiotti S, Quagliuolo VL, Lopez A, Grignani G, Blay JY, Brunello A, Gutierrez A, Valverde C, Hindi N, Dei AP, Picci P, Casali PG, Gronchi A. Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial. MOLECULAR CANCER THERAPEUTICS. 2021; 20(12). DOI:10.1158/1535-7163.MCT-21-0315. PMID:34552008. IF:6,009.
• Martin J, Pousa AL, Brohl AS, Van BA, Powers B, Stacchiotti S, Blay JY, Hu JS, Oakley GJ, Wang H, Szpurka AM, Levy DE, Mo G, Ceccarelli M, Jones RL. Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. MOLECULAR CANCER THERAPEUTICS. 2021; 20(1). DOI:10.1158/1535-7163.MCT-20-0441. PMID:33177152. IF:6,009.
• Martin M, Tobena M. First-Line Maintenance Treatment in Metastatic Colorectal Cancer (mCRC): Quality and Clinical Benefit Overview. Journal of Clinical Medicine. 2021; 10(3):470. DOI:10.3390/jcm10030470. PMID:33530547. IF:4,964.
• Martinez J, De Sande LM, Luna P, Martin J, Alvarez R, Marquina G, Diaz R, Poveda A, Cano JM, Cruz J, Pousa AL, Salgado M, Valverde CM, Sevilla I, Martinez J, Rubio J, De Juan A, Carrasco JA, Moura DS, Gurruchaga I, Gutierrez A. A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study. Cancers. 2021; 13(4):792. DOI:10.3390/cancers13040792. PMID:33672857. IF:6,575.
• Mezquita L, Preeshagul I, Auclin E, Saravia D, Hendriks L, Rizvi H, Park W, Nadal E, Martin P, Ruffinelli JC, Ponce S, Audigier C, Carnio S, Blanc F, Bironzo P, Tabbo F, Reale ML, Novello S, Hellmann MD, Sawan P, Girshman J, Plodkowski AJ, Zalcman G, Majem M, Charrier M, Naigeon M, Rossoni C, Mariniello A, Paz L, Dingemans AM, Planchard D, et al. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. EUROPEAN JOURNAL OF CANCER. 2021; 151. DOI:10.1016/j.ejca.2021.03.011. PMID:34022698. IF:10,002.
• Moreno V, Greil R, Yachnin J, Majem M, Wermke M, Arkenau HT, Basque JR, Nidamarthy PK, Kapoor S, Cui XM, Giovannini M. Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors. CLINICAL THERAPEUTICS. 2021; 43(6). DOI:10.1016/j.clinthera.2021.04.006. PMID:34053700. IF:3,637.
• Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grunwald V, Hutson TE, Kopyltsov E, Mendez MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Gordoa TA, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. NEW ENGLAND JOURNAL OF MEDICINE. 2021; 384(14). DOI:10.1056/NEJMoa2035716. PMID:33616314. IF:176,079.
• Osuna R, Arqueros C, Galano C, Mulet M, Zamora C, Barnadas A, Vidal S. Effector Mechanisms of CD8+HLA-DR+ T Cells in Breast Cancer Patients Who Respond to Neoadjuvant Chemotherapy. Cancers. 2021; 13(24):6167. DOI:10.3390/cancers13246167. PMID:34944786. IF:6,575.
• Palmero R, Taus A, Viteri S, Majem M, Carcereny E, Garde J, Felip E, Nadal E, Malfettone A, Sampayo M, Riva F, Nagy RJ, Lanman RB, Faull I, Dix D, Karachaliou N, Rosell R. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer. JCO Precision Oncology. 2021; 5. DOI:10.1200/PO.20.00241. PMID:34994593. IF:5,479.
• Powles T, Carroll D, Chowdhury S, Gravis G, Joly F, Carles J, Flechon A, Maroto P, Petrylak D, Rolland F, Cook N, Balar AV, Sridhar SS, Galsky MD, Grivas P, Ravaud A, Jones R, Cosaert J, Hodgson D, Kozarewa I, Mather R, McEwen R, Mercier F, Landers D. An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. NATURE MEDICINE. 2021; 27(5). DOI:10.1038/s41591-021-01317-6. PMID:33941921. IF:87,241.
• Provencio M, Gallego JMM, Calles A, Antonanzas M, Pangua C, Rubio XM, Nadal E, Castro RL, Lopez A, Del Barco E, Domine M, Franco F, Diz P, Sandoval C, Girona ES, Sullivan I, Sala MA, Ledo GG, Cucurull M, Mosquera J, Martinez M, Chara LE, Arriola E, Herrera BE, Jarabo JR, Alvarez RA, Baena J, Cao MG. Lung cancer patients with COVID-19 in Spain: GRAVID study. LUNG CANCER. 2021; 157. DOI:10.1016/j.lungcan.2021.05.014. PMID:34016490. IF:6,081.
• Provencio M, Majem M, Guirado M, Massuti B, de Las Penas R, Ortega AL, Domine M, Marse R, Sala MA, Paredes A, Moran T, Vazquez S, Coves J, Larriba JLG, Sanchez JM, Vicente D, Farre N, Fornos LF, Zapata I, Franco F, Serna R, Romero A, Isla D. Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection. LUNG CANCER. 2021; 153. DOI:10.1016/j.lungcan.2021.01.005. PMID:33453470. IF:6,081.
• Provencio M, Terrasa J, Garrido P, Campelo RG, Aparisi F, Diz P, Aguiar D, Garcia C, Hidalgo J, Aguado C, Gonzalez JG, Esteban E, Gomez L, Moran T, Juan O, Chara LE, Marti JL, Castro RL, Ortega AL, Moreno EM, Coves J, Pena A, Bosch J, Gastaldo AS, Nunez NF, del Barco E, Cobo M, Isla D, Majem M, Navarro F, Calvo V. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group. BMC CANCER. 2021; 21(1):230. DOI:10.1186/s12885-021-07922-5. PMID:33676426. IF:4,638.
• Redondo A, Guerra E, Manso L, Martin C, Martinez J, Perez JA, Varela MQ, Rubio MJ, Barretina MP, Gonzalez A. SEOM clinical guideline in ovarian cancer (2020). Clinical & Translational Oncology. 2021; 23(5). DOI:10.1007/s12094-020-02545-x. PMID:33515422. IF:3,340.
• Redondo A, Oaknin A, Rubio MJ, Barretina MP, de Juan A, Manso L, Romero I, Martin C, Poveda A, Gonzalez A. Management of advanced ovarian cancer in Spain: an expert Delphi consensus. Journal of Ovarian Research. 2021; 14(1):72. DOI:10.1186/s13048-021-00816-x. PMID:34039386. IF:5,506.
• Ribelles N, Alvarez I, Arcusa A, Chacon JI, de la Haba J, Garcia J, Garcia J, Jara C, Jerez JM, Lazaro M, Leon L, Ramirez N, Tibau A, Garcia A. Electronic health records and patient registries in medical oncology departments in Spain. Clinical & Translational Oncology. 2021; 23(10). DOI:10.1007/s12094-021-02614-9. PMID:33864619. IF:3,340.
• Riera P, Paez D. Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients. Expert Opinion on Drug Metabolism & Toxicology. 2021; 17(10). DOI:10.1080/17425255.2021.1974397. PMID:34486919. IF:4,936.
• Riudavets M, Bosch J, Cabezon L, Tain PD, Hernandez A, Alonso M, Blanco R, Galvez E, Insa A, Mielgo X, Moran T, Ponce S, Roa D, Sanchez JM, Majem M. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma. Clinical & Translational Oncology. 2021; 23(12). DOI:10.1007/s12094-021-02661-2. PMID:34292495. IF:3,340.
• Riudavets M, Sullivan I, Abdayem P, Planchard D. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations. ESMO Open. 2021; 6(5). DOI:10.1016/j.esmoop.2021.100260. PMID:34479034. IF:6,883.
• Rofes P, Gonzalez S, Navarro M, Moreno JM, Solanes A, Darder E, Carrasco E, Iglesias S, Salinas M, Gomez C, Velasco A, Tuset N, Varela M, Llort G, Cajal TRY, Grau E, Duenas N, Merlano ND, Matias X, Rivera B, Balmana J, Pineda M, Brunet J, Capella G, del Valle J, Lazaro C. Paired Somatic-Germline Testing of 15 Polyposis and Colorectal Cancer-Predisposing Genes Highlights the Role of APC Mosaicism in de Novo Familial Adenomatous Polyposis. JOURNAL OF MOLECULAR DIAGNOSTICS. 2021; 23(11). DOI:10.1016/j.jmoldx.2021.07.024. PMID:34454113. IF:5,341.
• Romero A, Jantus-Lewintre E, García-Peláez B, Royuela A, Insa A, Cruz P, Collazo A, Pérez Altozano J, Vidal OJ, Diz P, Cobo M, Hernández B, Vázquez Estevez S, Benítez G, Guirado M, Majem M, Bernabé R, Ortega AL, Blasco A, Bosch-Barrera J, Jurado JM, García González J, Viteri S, Garcia Giron C, Massutí B, Lopez Martín A, et al. Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial. Molecular Oncology. 2021;15(1):43-56. DOI:10.1002/1878-0261.12832. PMID: 33107189. IF:7,449.
• Rubio J, Algaba F, Gallardo E, Marcos JA, Climent MA, Maroto P, Arranz JÁ. Recent Advances in the Management of Patients with Non-Muscle-Invasive Bladder Cancer Using a Multidisciplinary Approach: Practical Recommendations from the Spanish Oncology Genitourinary (SOGUG) Working Group. Cancers. 2021; 13(19):4762. DOI:10.3390/cancers13194762. PMID:34638247. IF:6,575.
• Salazar J, Perez J, Salas K, Antequera A, Auladell A, Dorantes R, Meade AG, Quintana MJ, Requeijo C, Rodriguez G, Santero M, Acosta R, Sola I, Urrutia G, Cosp XB, Systemic Treatments Adv D. Efficacy of systemic oncological treatments in patients with advanced pancreatic cancer at high risk of dying in the short or medium-term: overview of systematic reviews. EUROPEAN JOURNAL OF CANCER. 2021; 154. DOI:10.1016/j.ejca.2021.05.034. PMID:34252759. IF:10,002.
• Santero M, Perez J, Acosta R, Meade AG, Antequera A, Auladell A, Quintana MJ, Requeijo C, Rodriguez G, Salas K, Dorantes R, Salazar J, Sola I, Urrutia G, Cosp XB. Efficacy of systemic oncological treatments in patients with advanced esophageal or gastric cancers at high risk of dying in the middle and short term: an overview of systematic reviews. BMC CANCER. 2021; 21(1):712. DOI:10.1186/s12885-021-08330-5. PMID:34134661. IF:4,638.
• Santos M, Lanillos J, Roldan JM, Caleiras E, Montero C, Cascon A, Climent MA, Anguera G, Hernando S, Lainez N, Robledo M, Robles L, de Velasco G, Garcia J, Rodriguez C. Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinoma. GENETICS IN MEDICINE. 2021; 23(4). DOI:10.1038/s41436-020-01062-0. PMID:33442023. IF:8,864.
• Sierra B, Cruz A, Nadal E, Garitaonaindia Y, Insa A, Mosquera J, Casal J, Domine M, Majem M, Rodriguez D, Martinez A, Carpeno JD, Cobo M, Vivanco GL, Del Barco E, Caro RB, Vinolas N, Aranda IB, Viteri S, Massuti B, Laza R, Casarrubios M, Garcia A, Romero A, Franco F, Provencio M. Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. Journal for ImmunoTherapy of Cancer. 2021; 9(8):e002804. DOI:10.1136/jitc-2021-002804. PMID:34446577. IF:12,469.
• Stacchiotti S, Miah AB, Frezza AM, Messiou C, Morosi C, Caraceni A, Antonescu CR, Bajpai J, Baldini E, Bauer S, Biagini R, Bielack S, Blay JY, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brodowicz T, Callegaro D, De Alava E, Deoras M, Dufresne A, Eriksson M, Errani C, Fedenko A, Ferraresi V, Ferrari A, Fletcher CDM, Del Muro XG, Gelderblom H, et al. [Pousa AL]. Enithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. ESMO Open. 2021; 6(3):100170. DOI:10.1016/j.esmoop.2021.100170. PMID:34090171. IF:6,883.
• Stjepanovic N, Lubinski J, Moller P, Armel SR, Foulkes WD, Tung N, Neuhausen SL, Kotsopoulos J, Sun P, Sun S, Eisen A, Narod SA, Cajal TR, Bordeleau LJ. Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers. BREAST CANCER RESEARCH AND TREATMENT. 2021; 187(2). DOI:10.1007/s10549-020-06072-9. PMID:33423179. IF:4,624.
• Strauss SJ, Frezza AM, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Blay JY, Bolle S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brennan B, Brodowicz T, Buonadonna A, de Álava E, Dei AP, Garcia del Muro X, Dufresne A, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Gaspar N, Gasperoni S, Gelderblom H, Gouin F, et al. [López A]. Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up?. ANNALS OF ONCOLOGY. 2021; 32(12). DOI:10.1016/j.annonc.2021.08.1995. PMID:34500044. IF:51,769.
• Vidal J, Casadevall D, Bellosillo B, Pericay C, Garcia R, Losa F, Layos L, Alonso V, Capdevila J, Gallego J, Vera R, Salud A, Martin M, Nogue M, Cillan E, Maurel J, Faull I, Raymond V, Fernandez C, Montagut C. Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD1402 Trial. CLINICAL CANCER RESEARCH. 2021; 27(10). DOI:10.1158/1078-0432.CCR-20-4769. PMID:33727257. IF:13,801.
• Vokinger KN, Hwang TJ, Daniore P, Lee CC, Tibau A, Grischott T, Rosemann TJ, Kesselheim AS. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe. JAMA Oncology. 2021; 7(9):e212026. DOI:10.1001/jamaoncol.2021.2026. PMID:34196656. IF:33,006.
• Wilson BE, Desnoyers A, Nadler MB, Tibau A, Amir E. Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations. Cancer Medicine. 2021; 10(16). DOI:10.1002/cam4.4029. PMID:34323019. IF:4,711.
• Wu YL, Tsuboi M, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng LM, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS. A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer. Future Oncology. 2021; 17(35). DOI:10.2217/fon-2021-0752. PMID:34723634. IF:3,674.
• Zamora C, Riudavets M, Anguera G, Alserawan L, Sullivan I, Barba A, Serra J, Ortiz MA, Gallardo P, Perea L, Gavira J, Barnadas A, Majem M, Vidal S. Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents. CANCER IMMUNOLOGY IMMUNOTHERAPY. 2021; 70(6). DOI:10.1007/s00262-020-02793-4. PMID:33388994. IF:6,630.